Transplantační medicína

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

In Vietnam, annual influenza hospitalizations among the elderly are 154% higher, and mortality rates 700% higher than in adults aged 50-64. Yet vaccination coverage in those 65 and older remains just 5.55%, well below the WHO target of 75%.

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet